<p>来自 JonesTrading 的分析师 Debanjana Chatterjee 对 EyePoint Pharmaceuticals 维持买入评级，并将目标价定为 43.00 美元。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，助您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
<p>Debanjana Chatterjee 的评级基于对 EyePoint Pharmaceuticals 的良好前景，特别是其湿性年龄相关性黄斑变性（wet AMD）疗法 Duravyu，预计将在 2026 年前有关键试验结果发布。该公司在湿性 AMD 批准方面采取了成熟的监管路径，这被视为相较于其他采取更创新方法的公司的战略优势。</p>
<p>EyePoint 的财务状况也很强劲，拥有可观的现金储备，为其持续和未来的研究与开发活动提供了坚实的基础。市场动态和湿性 AMD 治疗的潜在范式转变进一步支持了买入评级，因为 EyePoint 的疗法可能在满足该领域未满足的需求方面发挥重要作用。</p>
<p>在 12 月 9 日发布的另一份报告中，瑞穗证券也重申了对该股票的买入评级，目标价为 33.00 美元。</p>

EYPT

<p>分析师 Debanjana Chatterjee 来自 JonesTrading，维持对 EyePoint Pharmaceuticals 的买入评级，目标价为 43.00 美元，理由是其有前景的湿性年龄相关性黄斑变性治疗药物 Duravyu 以及强劲的财务状况。EyePoint 的战略监管路径和市场动态支持该评级。瑞穗证券也重申了买入评级，目标价为 33.00 美元</p>

<p>Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals and keeping the price target at $43.00.</p>
<div class="lb-trans"><p>来自 JonesTrading 的分析师 Debanjana Chatterjee 对 EyePoint Pharmaceuticals 维持买入评级，并将目标价定为 43.00 美元。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，助您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
</div><p>Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals, particularly with its wet AMD therapy, Duravyu, which is expected to have pivotal trial readouts by 2026. The company has pursued a well-established regulatory path for wet AMD approval, which is seen as a strategic advantage compared to other companies taking more innovative approaches.</p>
<div class="lb-trans"><p>Debanjana Chatterjee 的评级基于对 EyePoint Pharmaceuticals 的良好前景，特别是其湿性年龄相关性黄斑变性（wet AMD）疗法 Duravyu，预计将在 2026 年前有关键试验结果发布。该公司在湿性 AMD 批准方面采取了成熟的监管路径，这被视为相较于其他采取更创新方法的公司的战略优势。</p>
</div><p>EyePoint’s financial position is also strong, with significant cash reserves that provide a solid foundation for its ongoing and future research and development activities. The market dynamics and potential paradigm shifts in wet AMD treatments further support the Buy rating, as EyePoint’s therapies could play a significant role in addressing unmet needs in this space.</p>
<div class="lb-trans"><p>EyePoint 的财务状况也很强劲，拥有可观的现金储备，为其持续和未来的研究与开发活动提供了坚实的基础。市场动态和湿性 AMD 治疗的潜在范式转变进一步支持了买入评级，因为 EyePoint 的疗法可能在满足该领域未满足的需求方面发挥重要作用。</p>
</div><p>In another report released on December 9, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.</p>
<div class="lb-trans"><p>在 12 月 9 日发布的另一份报告中，瑞穗证券也重申了对该股票的买入评级，目标价为 33.00 美元。</p>
</div>

买入建议：EyePoint 制药的战略定位及其有前景的湿性年龄相关性黄斑变性（AMD）疗法